KeyOptions, having secured the rights to bring the Virolens® testing units to Australia, Latin America, South East Asia, Turkey and a number of other territories in conjunction with other partners. (Link to KeyOptions press release)” data-reactid=”14″CHICAGO, Sept. 13, 2020 (GLOBE NEWSWIRE) — Lord Global Corporation is issuing this clarifying press release relating to KeyOptions, having secured the rights to bring the Virolens® testing units to Australia, Latin America, South East Asia, Turkey and a number of other territories in conjunction with other partners. (Link to KeyOptions press release)
The Virolens®️ system is a COVID-19 screening device based on microscopic holographic imaging and artificial intelligence (AI) software technology. It uses a digital camera attached to a microscope to analyze saliva samples, with the data run through a computer which is trained to identify the virus from other cells, delivering an end result in just 20 seconds.
The Virolens®️ system was trained to recognize the COVID-19 virus particles in saliva using a range of samples of COVID-19 virus provided by virologists working on the virus at the University of Bristol. The Virolens®️ system has a 99.8% sensitivity and 96.7% specificity, based on the results of an internal in-vitro validation study, demonstrating an exciting proof of concept.
A user simply opens the cartridge lid, swabs their tongue, closes the cartridge and inserts it into the machine. Within seconds the presence or absence of Covid-19 is revealed via a red or green light, depending on the result.
link to Iabra press release), initial trial orders have now been secured with launch customers worldwide, including the London Heathrow Airport(Link to Video). Virolens® is embarking on clinical trials which would be necessary for it to be certified for medical use.” data-reactid=”22″Following the first round of field testing carried out by iAbra in partnership with London Heathrow Airport (link to Iabra press release), initial trial orders have now been secured with launch customers worldwide, including the London Heathrow Airport(Link to Video). Virolens® is embarking on clinical trials which would be necessary for it to be certified for medical use.
27Health Inc. has signed an administrative and financing agreement with KeyOptions. The terms of this administrative and financing agreement call for 27Health Inc. to receive a significant amount of KeyOption’s…
Read More: Lord Global Corporation joins with KeyOptions to market Virolens®, 20-second